SCHEMBL5540468

SCHEMBL5540468

Cc1ccc(N2CCC(O[C]=O)CC2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.47
ALDH1A1 P00352 2/20 0.47
GPR119 Q8TDV5 3/20 0.46
ADRB1 P08588 1/20 0.44
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
AKR1C3 P42330 1/20 0.40
SCN1A P35498 1/20 0.39
SCN2A Q99250 1/20 0.39
SCN3A Q9NY46 1/20 0.39
USP2 O75604 1/20 0.38
LMNA P02545 2/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
KDM4E B2RXH2 1/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
MCL1 Q07820 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
L3MBTL3 Q96JM7 1/20 0.37
CTSB P07858 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5536217 0.83 MBTD1 (0.47) MAPTALDH1A1GPR119ADRB1MEN1
SCHEMBL5540924 0.81 NOTUM (0.51) MAPTALDH1A1GPR119ADRB1L3MBTL1
SCHEMBL5534353 0.80 FFAR4 (0.43) MAPTGPR119L3MBTL1L3MBTL3
SCHEMBL5535612 0.80 NOTUM (0.50) GPR119AKR1C3
SCHEMBL171731 0.79 ADRB1 (0.50) MAPTALDH1A1GPR119ADRB1MEN1
SCHEMBL5538569 0.78 MAPT (0.46) MAPTALDH1A1MEN1KMT2ALMNA
SCHEMBL5542372 0.77 NOTUM (0.39) MAPTGPR119AKR1C3LMNAL3MBTL1
SCHEMBL5540472 0.77 MAPT (0.47) MAPTALDH1A1GPR119ADRB1MEN1
SCHEMBL23564134 0.76 MAPT (0.47) MAPTALDH1A1GPR119ADRB1MEN1
SCHEMBL5540349 0.75 MAPT (0.42) MAPTALDH1A1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 MAPT 4117/4885ALDH1A1 355/4885GPR119 658/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.